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Abstract
Objective: Four types of antipsychotic-induced movement disorders: tardive dyskinesia (TD), parkinsonism, akathisia and
tardive dystonia, subtypes of TD (orofacial and limb truncal dyskinesia), subtypes of parkinsonism (rest tremor, rigidity, and
bradykinesia), as well as a principal-factor of the movement disorders and their subtypes, were examined for association
with variation in 10 candidate genes (PPP1R1B, BDNF, DRD3, DRD2, HTR2A, HTR2C, COMT, MnSOD, CYP1A2, and RGS2).
Methods: Naturalistic study of 168 white long-stay patients with chronic mental illness requiring long-term antipsychotic
treatment, examined by the same rater at least two times over a 4-year period, with a mean follow-up time of 1.1 years, with
validated scales for TD, parkinsonism, akathisia, and tardive dystonia. The authors genotyped 31 SNPs, associated with
movement disorders or schizophrenia in previous studies. Genotype and allele frequency comparisons were performed with
multiple regression methods for continuous movement disorders.
Results: Various SNPs reached nominal significance: TD and orofacial dyskinesia with rs6265 and rs988748, limb truncal
dyskinesia with rs6314, rest tremor with rs6275, rigidity with rs6265 and rs4680, bradykinesia with rs4795390, akathisia with
rs4680, tardive dystonia with rs1799732, rs4880 and rs1152746. After controlling for multiple testing, no significant results
remained.
Conclusions: The findings suggest that selected SNPs are not associated with a susceptibility to movement disorders.
However, as the sample size was small and previous studies show inconsistent results, definite conclusions cannot be made.
Replication is needed in larger study samples, preferably in longitudinal studies which take the fluctuating course of
movement disorders and gene-environment interactions into account.
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Introduction
Antipsychotics are the central pillar in the treatment of
psychotic disorder. However, these agents can induce movement
disorders, which are associated with social stigmatization, physical
disabilities and poorer quality of life. They also contribute to non-
compliance, which results in an increased risk of psychotic relapse
[1–3]. Therefore, identification of patients that are prone to these
side effects would be of clinical value. Antipsychotic-induced
movement disorders [4,5] can be classified, on the one hand, into
acute syndromes, that appear within hours/days or weeks after
initiating antipsychotic treatment or increasing the antipsychotic
dose (or cessation of anticholinergics), e.g. parkinsonism and
akathisia, and, on the other hand, tardive syndromes, that develop
after months or years of treatment with antipsychotics such as
tardive dyskinesia (TD) and tardive dystonia. Initially, the term
‘tardive’ (delayed) was introduced to emphasize the late-onset
types of movement disorders occurring during antipsychotic use.
Yet the definition of tardive disorders in the current study
emphasizes their persistence, which is clinically more important
than their late-onset [5,6]. Given that combinations of acute and
chronic movement disorders occur in patients undergoing long-
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include both syndromes, i.e., the four major types of movement
disorders (TD, parkinsonism, akathisia and tardive dystonia).
Family studies suggest an important genetic component to the
risk for movement disorders [7–12]. A recent meta-analysis on the
prevalence of dyskinesia and parkinsonism reported spontaneous
dyskinesia and parkinsonism in antipsychotic naı ¨ve patients with
schizophrenia, and a higher prevalence of dyskinesia and
parkinsonism in healthy family members of patients with
schizophrenia, compared to matched controls [13].
Pharmacogenetic studies may identify genetic risk factors which
underlie individual differences in response to antipsychotics
[11,14,15], in theory paving the way for individually tailored
medication prescriptions [16]. Knowledge of a minimal number of
genetic susceptibility loci in candidate genes and demographic,
clinical and drug-related risk factors would help the clinician to
make a rational treatment choice.
It can be hypothesized that specific subtypes of movement
disorders are more suitable for genetic analysis than a general
movement disorder syndrome, as subtypes may better reflect the
underlying biological heterogeneity in complex syndromes.
The phenotypes under study were TD, parkinsonism, akathisia,
and tardive dystonia, subtypes of TD (orofacial and limb truncal
dyskinesia), subtypes of parkinsonism (rest tremor, rigidity, and
bradykinesia), as well as a principal-factor of the movement
disorders and their subtypes.
The 10 candidate genes were PPP1R1B, BDNF, DRD3, DRD2,
HTR2A, HTR2C, COMT, MnSOD, CYP1A2, and RGS2 (Text S1).
The choice of these genes was hypothesis-driven, under the
common disease/common variant (CDCV) hypothesis, which
proposes that common diseases may be caused by common genetic
variants [17–20].
The aim of the current study was to determine the association
between movement disorders and variations in these 10 candidate
genes.
The prospective design of the current study extends hitherto
cross-sectional work in the pharmacogenetic field of antipsychotic-
induced movement disorders. Indeed, prospective assessment of
fluctuating (repeated) movement disorders measures the pheno-
type more specifically and that increases the validity of the
associations between movement disorders and risk factors.
Methods
Ethics Statement
The protocol was approved by the standing Institutional Review
Board, ‘Medisch-ethische Toetsingscommissie Instellingen Gees-
telijke Gezondheidszorg’ (Review Board for Human Research in
Psychiatry), the Netherlands [protocol number 377].
Written informed consent was obtained from each patient,
hence, consent obtained from the next of kin was not necessary
and not recommended by the Review Board for Human Research
in Psychiatry.
Subjects
A 4-year prospective naturalistic study (July 2003–May 2007)
was conducted with 209 patients with chronic mental illness in
order to determine the genetic risk factors of the four major types
of movement disorders (TD, parkinsonism, akathisia, and tardive
dystonia), subtypes of TD and parkinsonism, as well as a principal-
factor of the movement disorders and their subtypes. To this end,
a cohort was drawn from a general psychiatric hospital (GGZ
Centraal, Amersfoort, the Netherlands). Full details of the study
design and movement disorders have been published previously
[21] (Bakker and colleagues, submitted). The cohort was
representative of the population of patients with the most severe
chronic mental illness requiring long-stay care, given that the
hospital serves an epidemiological catchment area, is the only
institute providing this type of care in this area, and patients were
selected from a comprehensive list of all inpatients.
Of the patients assessed at baseline (N=207) 93.7% (n=194)
had at least one follow-up and 59.4% (n=123) had two follow-up
assessments. Loss to follow-up was due to patients who were
difficult to trace after leaving hospital, died or refused assessment
after inclusion.
Assessment
Patients were examined by a trained psychiatrist (PRB), using
a standard protocol, described by van Harten and colleagues [22].
In addition, subtypes of movement disorders were assessed using (i)
the Abnormal Involuntary Movement Scale (AIMS) [23,24] with
items 1–4 for orofacial and items 5–7 for limb truncal dyskinesia,
(ii) the Unified Parkinson Disease Rating Scale (UPDRS) [25] with
item c3–c4 for ‘rest tremor’ (rest tremor, and action/postural
tremor of hands); item c5 for rigidity; and items c1, c2, c6–c12,
and c14 for bradykinesia. This approach has been described
previously by 3 members of our research team (AAH, JvO and
PvH) [26–28].
As movement disorders likely share genetic liability, a genetic
association between the combined movement disorders and
candidate genes is also required. To determine the association
between the combined movement disorder and variation in 10
candidate genes, a principal-factor of the four major types of
movement disorders and subtypes of TD and parkinsonism was
calculated with the FACTOR procedure in the STATA statistical
program [29].
Based on the literature published between 1976 and August
2011, we selected 10 candidate genes (Table S1 and Text S1) that
(i) are involved in the dopaminergic and serotonergic systems
which have been implicated in the development of movement
disorders, and the gene coding for the free radical scavenging
enzymes like manganese super oxide dismutase (MnSOD) based on
the hypothesis of neuronal degeneration owing to toxic effects of
free radicals on TD. Genes involved in the glutamatergic system
that may also contribute to cumulative neural damage, were not
selected as the extensive number of receptors in this system, like
metabotropic receptors (mGluRs) and ionotropic receptors
(iGluRs), merit separate analysis.
In addition, variables possibly affecting risk were extracted from
patients’ case notes including age, sex, BMI, self-reported
handedness, diagnosis according to DSM-IV, ethnic group
(classified as white and non-white), duration of hospitalization
and history of electroconvulsive therapy (ECT). Negative symp-
toms were rated using the negative symptom subscale of the
Positive and Negative Symptom Severity (PANSS) scale [30]. The
MINI sections for alcohol and drug use were administered, and
information on tobacco intake (yes/no, number of cigarettes,
cigars, etc; descriptors such as ‘light’, ‘mild’, ‘heavy’ and ‘normal’
use of tobacco) was collected. At baseline and at each follow-up
assessment, current use of antipsychotic and anticholinergic
medication was collected, and the global symptom rating of the
Clinical Global Impression – Schizophrenia severity of illness
(CGI-SCH SI) scale was completed. All clinical assessments were
carried out by a psychiatrist (PRB). Information on current use of
the above medication was collected from the hospital and
outpatient pharmacy databases.
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295.30, 295.10, 295.20, 295.90, 295.60, 295.70, and other
diagnoses of ‘psychotic disorder’ to 295.40, 297.1, 298.8, 298.9.
DNA Extraction, Genotyping
Two 10 ml EDTA tubes of peripheral blood were drawn from
participants, and genomic DNA was extracted from leucocytes by
Autopure LS method (Qiangen) according to the manufacturer’s
protocols. We genotyped 31 SNPs (TaqManH SNP Genotyping
Assays method, Applied Biosystems, Foster City, California, USA)
in 10 candidate gene regions, including SNPs previously reported
as associated with movement disorders and schizophrenia.
Statistical Analyses
Hardy weinberg equilibrium. Only SNPs were included in
the analyses that were not significantly outside Hardy-Weinberg
Equilibrium (HWE) (p.0.05) in (i) the complete control sample
(for a dichotomous trait) or (ii) the complete study sample (for
a continuous trait). For the three SNPs in the X-chromosomal
HTR2C gene, departure from HWE was not calculated.
Departure from the HWE was calculated with the GENASS
and GENHW procedures in the STATA statistical program [29]
for (i) the dichotomously defined persistent forms of movement
disorders separately in both patients (with one movement disorder)
and controls (without that movement disorder), respectively. Case
definition of a persistent movement disorder was based on 2
consecutive assessments over a period of minimally 3 months, and
required that individuals met case definition criteria at two
consecutive assessments (hereafter: persistent movement disorder),
meeting the requirements of Schooler and Kane’s criteria for
persistent movement disorder [31], and (ii) the combined group of
patients and controls, as continuous measures cannot be separated
in both patients and controls.
Association tests for single SNPs. Only continuous move-
ment disorder outcomes were used, given that continuous
measures better handle the variability of movement disorders
and generate more statistical power than cut off points [32,33].
Genotype and allele frequency comparisons were performed with
multiple regression methods for continuous movement disorders,
using the Armitage trend test, with the major allele (from our
dataset of 168 selected white patients) as reference. The Armitage
trend test assumes an additive effect by both alleles on the trait of
interest, i.e. the mean effect on the trait by the heterozygous
genotype (Major-Minor) is halfway the effects of the two
homozygotes. (Major-Major and Minor-Minor).
Regression analyses. The regression analyses were con-
ducted with movement disorder measures at a single assessment
(hereafter: fluctuating movement disorder). The reason for this was
that movement disorders constantly fluctuate over time, so that
inclusion in the regression of their repeated single-occasion
measures allowed for calculation of associations between one
movement disorder with the other over time. As the study design
comprised repeated measures nested in the same patient,
clustering of observations in individuals needed to be corrected
for. Therefore, multilevel random regression was used with the
measurement occasion (baseline and two follow-ups) at level 1, and
subjects at level 2, with the XTREG MLE routine of the STATA
statistical program [29]. Associations with explanatory variables
were expressed as beta coefficients representing the change of
continuous movement disorder outcome with 1 unit change of the
exposure variable.
Using the dataset of 168 selected white patients, associations
with predictors were adjusted for a priori, movement-disorder
specific covariates as follows (Bakker and colleagues, submitted)
age was adjusted for in the model of TD and TD subtypes; age
and total antipsychotic use was adjusted for in the model of
parkinsonism and its subtypes, and no covariates were introduced
in the models of akathisia, tardive dystonia and the principal-
factor.
Power calculations were performed using the Quanto program
version 1.2.4 (http://hydra.usc.edu/gxe).
Correction for multiple testing. In order to correct for
multiple testing of single SNP tests, the Simes modification of the
Bonferroni multiple-testing procedure was performed to control
the False Discovery Rate (FDR) [34]. Bonferroni correction is too
conservative if tests are not independent of each other (as in this
case when there is LD between markers); in this case FDR
represents a less conservative alternative. We used the MULT-
PROC procedure in the STATA statistical program [29] for FDR
calculation, and then the SMILEPLOT procedure calling
MULTPROC to build a smile plot. A smile plot summarizes
a set of multiple analyses, similarly as a Cochrane forest plot
summarizes a meta-analysis, and separates by reference line
rejected and non-rejected p-values (on a reverse log scale against
the corresponding parameter estimates).
Defined daily dose. Antipsychotic doses were converted to
defined daily dose (DDD), for which we refer to our previous
publications [21] (Bakker and colleagues, submitted). Anticholin-
ergic medication was modeled as a dichotomous variable (yes/no).
Results
Sample Characteristics
Over the period of observation (mean=1.1 years, SD=0.64), of
the 209 patients included at baseline, 207 participated in the study.
One patient developed a brain tumor, another patient died after
inclusion. All patients had a history of cumulative antipsychotic
intake of minimally 1 year. Attrition rate was low at 9.8% over a 4-
year period.
Of the 207 patients, with chronic psychiatric illness requiring
long-term admission, 199 participated in the genetic study. To
prevent ethnic stratification resulting in spurious associations
owing to differences in allele frequencies and risk of movement
disorders, only white patients, representing the most prevalent
group (168=84.4%), were included in the analysis. At baseline,
mean age expressed in years was 48.8 (SD 12.4); men 48.6 (SD
12.5) and women 49.1 (SD 12.2). Age at first admission, expressed
in years, was 25.1 (SD 8.8); men 23.7 (SD 7.8) and women 27.1
(SD 9.7), respectively. The total duration of admission, expressed
in years, was 23.4 (SD 12.9), men 24.4 (SD 12.5) and women 22.0
(SD 13.4). Diagnoses according to DSM-IV Axis I as defined
above were: schizophrenia 112 (66.7%), psychosis 9 (5.4%),
affective disorder 27 (16.1%), other Axis I diagnosis 11 (6.6%) and
no Axis I diagnosis 9 (5.4%).
Association Analyses with SNPs
Six redundant SNPs owing to strong linkage disequilibrium
(LD) (Levwontin’s D’=1, R-squared=1) were removed (Table S1):
rs879606, rs907094, rs3764353, rs3764352 in PPP1R1B, and
rs4606 and rs1819741 in RGS2.
The following SNPs were excluded from analysis, due to
deviation from HWE: all movement disorders – rs6280, as well as
controls; TD - rs4795390; orofacial dyskinesia - rs4795390,
rs1800497; limb truncal dyskinesia - rs1800497; bradykinesia -
rs1799732, rs6311.
The (multilevel) regression yielded significant coefficients, after
adjustment for age, between tardive dyskinesia and rs6265
(B=0.19, p=0.0072) as well as rs988748 (B=0.18, p=0.0076);
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well as rs988748 (B=0.23, p=0.0019); and between limb truncal
dyskinesia and rs6314 (B=20.24, p=0.0357). After adjustment
for age and total antipsychotic DDD, associations were apparent
between rest tremor and rs6275 (B=20.14, p=0.0140); between
rigidity and rs6265 (B=20.15, p=0.0482) as well as rs4680
(B=0.14, p=0.0303); and between bradykinesia and rs4795390
(B=0.16, p=0.0451). Without adjustment, associations were
apparent between akathisia and rs4680 (B=0.13, p=0.0289);
between tardive dystonia and rs1799732 (B=0.04, p=0.0494),
rs4880 (B=20.03, p=0.0399), as well as rs1152746 (B=0.03,
p=0.0456). After Simes correction for multiple testing of the
above mentioned analyses, the number of rejected p-values was
zero, with a corrected overall critical p-value of 0.00021 (Figure 1).
Power calculations showed that our sample was insufficiently
powered (0.05%) to identify the betas from our regressions, which
were between 20.28 and 0.22.
Discussion
In a population with chronic mental illness, various SNPs in 10
candidate genes (PPP1R1B, BDNF, DRD3, DRD2, HTR2A,
HTR2C, COMT, MnSOD, CYP1A2, and RGS2) reached nominally
significant (p#0.05) associations with drug-induced movement
disorder. However, after controlling for multiple testing, our
findings suggest that these single nucleotide polymorphism (SNP)
are not associated with a susceptibility to movement disorders.
Another reason for the inconclusive findings could be explained
by the fact that in a naturalistic setting it is possible to evaluate the
overall impact of pharmacogenetic signals in the presence of a host
of real-life variables that can override pharmacogenetic variation.
The fact we did not observe a significant association may also
attest to the possibility that each gene makes a small contribution
that is often diluted or overridden by environmental and clinical
variations.
Limitations
This study had limitations, for which we refer to our previous
publications [21] (Bakker and colleagues, submitted) and addi-
tional limitations. First, as mentioned before, the relatively small
sample size was the major limitation in this study. Still, the power
in the current study may be increased as our patients had chronic
mental illness, with a mean total duration of admission of 23.4 yrs
(SD 12.9), which is a relatively long time for genetically susceptible
patients to develop movement disorder. Also, we used continuous
measures of movement disorder, which as a so-called intermediate
quantitative trait is more informative about the underlying path in
complex genetic diseases and thus generates more statistical power
[32,33]. In addition, we used repeated measures for continuous
movement disorders, which may give a more stable phenotype,
and thus more power.
Second, some authors may argue that association studies of
movement disorders in patient with a psychotic disorder will
produce non-significant results, as this model is inadequate since
movement disorders may share risk alleles with schizophrenia
[13]. However, many movement disorders and schizophrenia are
complex diseases caused by multiple genetic and environmental
factors, which are probably only partly shared, as (i) clinical
heterogeneity in schizophrenia is clear, (ii) evidence of pathophys-
iological and etiological heterogeneity is accumulating [35,36],
and (iii) TD is a predictor for poor outcome of schizophrenia [37].
Hence, it can be hypothesized that patients with movement
disorders represent a subgroup of schizophrenia and the above
mentioned model is adequate.
Third, some authors may contend that medication is an
important confounder, which should have been included in our
analysis. However, a confounding mechanism is difficult to
envisage, as choice of medication would need to be associated
with an SNP and, independently thereof, with the movement
disorder outcome. Nevertheless, medication may modify SNP-
Figure 1. Smile plot summarizing set of multiple analyses after Simes correction for multiple testing. Corresponding p-values (on
a reverse log scale against the corresponding parameter estimates). TD=tardive dyskinesia, OF=orofacial dyskinesia, LT=limb truncal dyskinesia,
PK=parkinsonism, RT=rest tremor, RG=rigidity, BK=bradykinesia, AK=akathisia, TDt=tardive dystonia and PF=principal-factor.
doi:10.1371/journal.pone.0036561.g001
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analyses as an interaction term.
Strengths
We refer to our previous publications [21] (Bakker and
colleagues, submitted). The importance of repeated measures
should be noted, as case definition of repeated measures, rather
than a single cross-sectional measure, for continuous movement
disorders better reflects the continuously fluctuating nature in time
of movement disorders, and therefore may represent a more
suitable standard in future research. To the best of our knowledge
only few papers in the literature address this issue.
As the sample size of the current study is small with low power
and previous studies show inconsistent results, definite conclusions
cannot be made. Yet the question is how to interpret these results.
In our opinion, the findings of weak genetic signals need to be
replicated in larger study samples, preferably in longitudinal
studies which take the fluctuating course of movement disorders
and gene-environment interactions into account [38,39]. Even
though the current study is inconclusive, negative studies also
ought to be reported as otherwise meta-analytic results in the
future can be biased by positive studies that tend to be published
more readily.
Various combinations of susceptibility genes may converge on
synaptic processing in microcircuits, affecting a final common
pathway of dysfunction and related symptoms, and secondary
morphological alterations [40,41]. However, despite growing
evidence from genetic association studies, genetics only explains
a minor part of schizophrenia, a fact which supports the
importance of other interacting factors, such as environmental
factors, which play important roles in schizophrenia [38].
Neuropsychiatric disorders may reflect the complex interplay of
not only genetic factors, but first and foremost of epigenetic,
stochastic, and non-genetic factors [42]. Consequently, at the
moment it is too early to describe a genetic pathway of
schizophrenia [38] or movement disorders.
An important development in human (pharmaco) genetics since
2005 is the possibility of genome-wide association studies (GWASs)
[43] which have the advantage of a ‘hypothesis free’ and hence
unbiased approach for examining new DNA variants which
influence genetic susceptibility to many common diseases and can
thus elucidate as yet unknown pathophysiological mechanisms.
After the choice of candidate genes in the current genetic
association study was made, three GWASs of movement disorders
were published: (i) the study by Inada e.a. [44] suggesting
involvement of the GABA receptor signaling pathway in the
development of therapy-resistant tardive dyskinesia, (ii) the study
by Akelai e.a. [45] specifying EPF1, NOVA1, and FIGN as
promising genes related to antipsychotic-induced parkinsonism,
and (iii) the study by A ˚berg [46] determining an association
between parkinsonism and a SNP in ZNF202, a transcriptional
repressor controlling the major protein in myelin, PLP1, related
both to Pelizaeus-Merzbacher disease with parkinsonism as
symptom, and schizophrenia.
The Psychiatric GWAS Consortium (PGC) has suggested that
in the near future larger GWAS samples will detect more variants
of common susceptibility with smaller effect sizes and that meta-
analyses of GWAS should find more conclusive evidence for
genetic associations. Meanwhile, new potentially promising genetic
techniques are being implemented such as epigenetics and whole-
exome sequencing as an alternative study design. Rare variants
detected by these next generation sequencing technologies may
yield a stronger signal than GWAS approaches. In our view, the
common variant common disease/phenotype approach is chal-
lenged including the area of pharmacogenetics. Rare variants
warrant more attention in future studies. Also, gene-environment-
wide interaction studies (GEWIS) approaches are being suggested
[47]. It seems legitimate to conclude that these new techniques
offer more effective genetic linkage and association studies.
There is a need for more participatory research designs,
especially in naturalistic studies in personalized medicine including
psychiatry. However, Lehoux and colleagues pose the following
question to be answered: ‘what value does personalized medicine
bring to health care?’ [48] This important question refers to the
unique context of personalized medicine where economic, political
and social issues come together.
In conclusion, the findings suggest that selected SNPs are not
associated with a susceptibility to movement disorders. However,
replication is needed in larger study samples, preferably in
longitudinal studies which take the fluctuating course of movement
disorders and gene-environment interactions into account. The
use of intermediate phenotypes, for example, laboratory based
phenotypes [42], or more accurate measures of movement
disorders, for example instrument measurement of lingual force
variability as proposed by Koning and colleagues [49], which may
represent a powerful alternative since instrument measurement
detects subclinical movement disorders and is highly reliable.
Moreover, (pharmaco) genetic studies may help elucidate common
pathways in the development of movement disorders. With this
information, an alternative World Health Organization Model
List of Essential Medicines may be one that lists the ‘minimal
essential biomarkers’ required for optimal pharmacotherapy [50].
However, on balance, our findings should be set in the context
of interactions with both other genetic susceptibility loci and
environmental factors, and, as rightly stated by Faraone and
colleagues [51] ‘‘any conclusion about the role of genes
and environment must rely not on a single study or class of study
but on the converging evidence provided by a variety of research
paradigms.’’
Future research on movement disorders may be served by the
inclusion of all four movement disorder, as performed in the
current study, since they may represent pleiotropic effects from
(partly) shared genetic factors [52].
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